CAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care, a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the appointment of Ariel Sutton to the newly-created position of General Manager of the company’s Stroke business.
“I am honored to take on this new role as Imperative Care continues to drive a patient-first approach to stroke treatment,” said Ariel. “Our approach has always been to focus on the needs of the patient and to work closely with physicians to rapidly iterate our product. Our commitment to addressing urgent clinical needs in collaboration with physicians has enabled us to continually elevate patient outcomes. I am excited to have this opportunity as Imperative Care advances toward its next chapter of growth.”
Ariel joined Imperative Care in August of 2016 as EVP, Marketing, and since then has played an instrumental role in steering the direction of the company from the first patient treated to 25,000 patients treated. Under Ariel’s leadership of the commercial organization, Imperative Care has become a leader in the highly competitive stroke market in just over three years since launching its first products.
Prior to joining Imperative Care, Ariel had key marketing and product management roles at Cardinal Health, Access Closure, ev3, FoxHollow Technologies, and Johnson & Johnson’s LifeScan division. She graduated from Brown University with an Sc.B. in biomedical engineering and earned her M.B.A. at Northwestern University’s Kellogg School of Management. She was awarded a U.S. State Department Fulbright Scholarship.
“Under Ariel’s leadership, Imperative Care has remained focused on elevating care and bringing life-saving technologies to patients affected by stroke,” said Daniel Davis, Imperative Care’s President and Chief Operating Officer. “Ariel’s dedication to excellence is unwavering, and I am looking forward to her leading Imperative Stroke through our next chapter as we continue to expand our clinical impact.”
In the United States, 800,000 people have a stroke each year.1 Stroke is a leading cause of death and serious long-term disability globally. The field of stroke treatment has advanced dramatically over the past decade, and clot-removing thrombectomy procedures have been found to significantly improve functional independence at 90 days.2,3 Recently published randomized studies in The New England Journal of Medicine have provided additional evidence to support the clinical benefits of thrombectomy procedures.4,5,6 These studies demonstrated that thrombectomy is beneficial for patients who have a large stroke and present within 24 hours of onset. This expands the treatment options available to a larger population of patients, offering new hope for stroke patients and their families.
Imperative Care’s products represent a new era in stroke thrombectomy that has enabled fast and consistent stroke treatment and improved procedure outcomes by helping physicians get closer to the treatment site for quicker, more efficient stroke procedures. These products are designed with the aim of allowing physicians to achieve complete reperfusion of the target vessel – known as TICI 3 – within 10 minutes. The company’s Zoom Stroke Solution product platform provides access through reperfusion for fast and effective clot removal in patients with acute ischemic stroke.
The Zoom Stroke Solution platform includes:
- Two large-bore .088” guide catheters – Zoom 88 and Zoom RDL – which enable intracranial access from two access points
- Four vessel-matched aspiration catheters that feature the unique TRXTM Tip, which provides 15% more surface area to engage the clot
- The Zoom Pump, which provides the strongest aspiration force on the market to remove clot from the brain
- Zoom POD, the only clot filter device on the market that provides immediate verification of clot-capture within the sterile field
1. Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association. Circulation. 2022;145(8):e153–e639.
2. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 2016; 387: 1723-31.
3. Jovin TG, Nogueira RG, Lansberg MG, et al. Thrombectomy for anterior circulation stroke beyond 6 h from time last known well (AURORA): a systematic review and individual patient data meta-analysis. Lancet 2022; 399:249.
4. Sarraj A, Hassan AE, Abraham MG, et al. Trial of endovascular thrombectomy for large ischemic strokes. N Engl J Med. 2023; DOI: 10.1056/NEJMoa2214403.
5. Yoshimura, MD, et al. Endovascular Therapy for Acute Stroke with a Large Ischemic Region. N Engl J Med 2022; DOI: 10.1056/NEJMoa2118191.
6. Xiaochuan Huo, MD, et al. Trial of Endovascular Therapy for Acute Ischemic Stroke with Large Infarct. N Engl J Med. 2023; DOI: 10.1056/NEJMoa2213379
About Imperative Care, Inc.
Imperative Care is a commercial-stage medical technology company researching and developing connected innovations to elevate care for people affected by devastating vascular diseases such as stroke and pulmonary embolism. The company has four businesses focused on addressing specific gaps in treatment and care to make an impact across the entire patient journey. Imperative Care is based in Campbell, Calif. https://imperativecare.com.
